Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
China Isotope & Radiation Corporation (1763.HK)
Beijing, CN
China Isotope & Radiation Corporation is dedicated to the development, production, and distribution of diagnostic and therapeutic radiopharmaceuticals, as well as radioactive source products for both medical and industrial applications throughout China. The company's operations are divided into five principal areas. Its Pharmaceuticals division focuses on creating and marketing imaging diagnostic and therapeutic radiopharmaceuticals, UBT kits and analyzers, and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment furnishes medical and industrial radioactive sources, along with associated technical support services. The Irradiation segment offers sterilization services for products such as medical devices, food, traditional Chinese medicine, and cosmetics, in addition to providing engineering, procurement, and construction (EPC) services for gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment handles the sale of radiation therapy equipment and its corresponding maintenance. Finally, the Independent Clinical Medical and Laboratory Services, and Other Business segment delivers independent clinical laboratory services to hospitals and other medical institutions, covering a range of conditions including hepatitis, endocrine disorders, bone metabolism issues, cardiovascular diseases, and diabetes. Founded in 1983, the company's main office is located in Beijing, China, and it operates as a subsidiary of China National Nuclear Corporation.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.24% | +4.72% | -4.52% | -13.19% | -18.91% | -11.04% | +41.27% | +9.84% | -40.10% | -10.60% | -10.60% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-7.6% Q4'25: +6.4% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%-21.3% Q4'25: -39.5% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+5.5% Q4'25: +9.5% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+13.1% ★ Q4'25: +11.4% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+7.3% ★ Q4'25: +13.7% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×2.33× Q4'25: 1.16× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.24B
est: 3.67B (-11.8%)
|
3.99B
est: 4.34B (-8.0%)
|
4.27B
est: 4.92B (-13.1%)
|
5.14B
est: 6.63B (-22.5%)
|
6.15B
est: 6.39B (-3.9%)
|
6.63B
est: 7.43B (-10.7%)
|
7.57B
est: 8.12B (-6.7%)
|
8.49B
8.49B – 8.49B
+4.5% YoY
|
9.35B
9.35B – 9.35B
+10.1% YoY
|
10.28B
10.28B – 10.28B
+10.0% YoY
|
| EBITDA |
774.44M
est: 637.34M (+21.5%)
|
801.69M
est: 639.08M (+25.4%)
|
717.43M
est: 677.37M (+5.9%)
|
901.43M
est: 797.08M (+13.1%)
|
1.05B
est: 969.27M (+8.8%)
|
1.22B
est: 1.16B (+5.5%)
|
1.28B
est: 1.41B (-8.9%)
|
1.47B
1.47B – 1.47B
+4.5% YoY
|
1.62B
1.62B – 1.62B
+10.1% YoY
|
1.78B
1.78B – 1.78B
+10.0% YoY
|
| EBIT |
700.33M
est: 518.53M (+35.1%)
|
670.01M
est: 834.10M (-19.7%)
|
580.55M
est: 837.51M (-30.7%)
|
742.85M
est: 985.53M (-24.6%)
|
874.88M
est: 1.20B (-27.0%)
|
958.58M
est: 1.43B (-33.1%)
|
1.06B
est: 1.14B (-6.9%)
|
1.19B
1.19B – 1.19B
+4.5% YoY
|
1.31B
1.31B – 1.31B
+10.1% YoY
|
1.44B
1.44B – 1.44B
+10.0% YoY
|
| Net Income |
322.95M
est: 375.54M (-14.0%)
|
329.03M
est: 397.13M (-17.1%)
|
213.58M
est: 382.41M (-44.1%)
|
335.75M
est: 450.00M (-25.4%)
|
392.28M
est: 547.21M (-28.3%)
|
370.97M
est: 654.67M (-43.3%)
|
406.65M
est: 536.96M (-24.3%)
|
529.42M
529.42M – 529.42M
-1.4% YoY
|
573.82M
573.82M – 573.82M
+8.4% YoY
|
655.79M
655.79M – 655.79M
+14.3% YoY
|
| SGA |
1.70B
est: 1.43B (+19.2%)
|
2.18B
est: 2.11B (+3.1%)
|
1.89B
est: 2.53B (-25.2%)
|
2.32B
est: 2.98B (-22.1%)
|
2.36B
est: 3.62B (-34.7%)
|
2.40B
est: 4.33B (-44.5%)
|
2.33B
est: 2.98B (-22.0%)
|
3.12B
3.12B – 3.12B
+4.5% YoY
|
3.43B
3.43B – 3.43B
+10.1% YoY
|
3.78B
3.78B – 3.78B
+10.0% YoY
|
| EPS |
1.16
est: 1.17 (-1.2%)
|
1.03
est: 1.38 (-25.3%)
|
0.67
est: 1.06 (-36.6%)
|
1.05
est: 1.22 (-13.6%)
|
1.23
est: 1.32 (-6.5%)
|
1.16
est: 1.50 (-22.8%)
|
1.27
est: 1.68 (-24.3%)
|
1.66
1.66 – 1.66
-1.4% YoY
|
1.79
1.79 – 1.79
+8.4% YoY
|
2.05
2.05 – 2.05
+14.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 12.6K | 0.42% |
| 2 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 27.1K | 0.44% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 192.4K | 0.39% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 98.0K | 0.28% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 60.2K | 0.29% |
| 6 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 31.3K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Junqi Zhang | GM & Executive Director | 2M | male |
| Jin Du | Chief Engineer | 1M | male |
| Yingying Huo | Executive Director | 1M | female |
| Xiaoyu Ma | Executive Director | 1M | female |
| Yafei Xiao | Chairman | 588.1K | male |
| Yuntao Liu | Deputy GM & Chief Engineer | — | male |
| Sau In Kwan | Joint Secretary | — | female |
| Cangren Wang | Chief Accountant, Joint Secretary & General Legal Counsel | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1763.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
